Show simple item record

dc.contributor.authorAbou-Alfa, G
dc.contributor.authorQin, S
dc.contributor.authorRyoo, B
dc.contributor.authorLu, S
dc.contributor.authorYen, C
dc.contributor.authorFeng, Y
dc.contributor.authorLim, H
dc.contributor.authorIzzo, F
dc.contributor.authorColombo, M
dc.contributor.authorSarker, D
dc.contributor.authorBolondi, L
dc.contributor.authorVaccaro, G
dc.contributor.authorHarris, W
dc.contributor.authorChen, Z
dc.contributor.authorHubner, Richard A
dc.contributor.authorMeyer, T
dc.contributor.authorSun, W
dc.contributor.authorHarding, J
dc.contributor.authorHollywood, E
dc.contributor.authorMa, J
dc.contributor.authorWan, P
dc.contributor.authorLy, M
dc.contributor.authorBomalaski, J
dc.contributor.authorJohnston, A
dc.contributor.authorLin, C
dc.contributor.authorChao, Y
dc.contributor.authorChen, L
dc.date.accessioned2018-05-10T20:22:45Z
dc.date.available2018-05-10T20:22:45Z
dc.date.issued2018-04-05
dc.identifier.citationADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. 2018, Ann Oncolen
dc.identifier.issn1569-8041
dc.identifier.pmid29659672
dc.identifier.doi10.1093/annonc/mdy101
dc.identifier.urihttp://hdl.handle.net/10541/620997
dc.description.abstractArginine depletion is a putative target in hepatocellular carcinoma (HCC). HCC often lacks argininosuccinate synthetase, a citrulline to arginine-repleting enzyme. ADI-PEG 20 is a cloned arginine degrading enzyme - arginine deiminase - conjugated with polyethylene glycol. The goal of this study was to evaluate this agent as a potential novel therapeutic for HCC after first line systemic therapy.
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncologyen
dc.titleADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NYen
dc.identifier.journalAnnals of Oncologyen
html.description.abstractArginine depletion is a putative target in hepatocellular carcinoma (HCC). HCC often lacks argininosuccinate synthetase, a citrulline to arginine-repleting enzyme. ADI-PEG 20 is a cloned arginine degrading enzyme - arginine deiminase - conjugated with polyethylene glycol. The goal of this study was to evaluate this agent as a potential novel therapeutic for HCC after first line systemic therapy.


This item appears in the following Collection(s)

Show simple item record